JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Danaher Corp

Closed

SectorHealthcare

223.58 0.49

Overview

Share price change

24h

Current

Min

223.09

Max

223.98

Key metrics

By Trading Economics

Income

-399M

555M

Sales

195M

5.9B

P/E

Sector Avg

44.433

37.461

EPS

0.77

Dividend yield

0.56

Profit margin

9.35

Employees

61,000

EBITDA

-455M

1.3B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+9.17% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.56%

2.33%

Next Dividend date

31 Oct 2025

Market Stats

By TradingEconomics

Market Cap

15B

150B

Previous open

223.09

Previous close

223.58

News Sentiment

By Acuity

39%

61%

111 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Danaher Corp Chart

Past performance is not a reliable indicator of future results.

Related News

21 Oct 2025, 17:41 UTC

Earnings

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21 Oct 2025, 10:28 UTC

Earnings

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22 Jul 2025, 11:32 UTC

Earnings

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 Jul 2025, 10:42 UTC

Earnings

Danaher Posts Higher 2Q Sales, Lower Profit

22 Apr 2025, 10:34 UTC

Earnings

Danaher 1Q Results Decline But Top Estimates

21 Oct 2025, 10:02 UTC

Earnings

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21 Oct 2025, 10:01 UTC

Earnings

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21 Oct 2025, 10:01 UTC

Earnings

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21 Oct 2025, 10:00 UTC

Earnings

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21 Oct 2025, 10:00 UTC

Earnings

Danaher 3Q Net $908M >DHR

21 Oct 2025, 10:00 UTC

Earnings

Danaher 3Q Sales $6.05B >DHR

21 Oct 2025, 10:00 UTC

Earnings

Danaher 3Q Adj EPS $1.89 >DHR

21 Oct 2025, 10:00 UTC

Earnings

Danaher 3Q EPS $1.27 >DHR

22 Jul 2025, 10:03 UTC

Earnings

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 Jul 2025, 10:03 UTC

Earnings

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 Jul 2025, 10:02 UTC

Earnings

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 Jul 2025, 10:01 UTC

Earnings

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 Jul 2025, 10:00 UTC

Earnings

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 Jul 2025, 10:00 UTC

Earnings

Danaher 2Q Net $555M >DHR

22 Jul 2025, 10:00 UTC

Earnings

Danaher 2Q Sales $5.9B >DHR

22 Jul 2025, 10:00 UTC

Earnings

Danaher 2Q Adj EPS $1.80 >DHR

22 Jul 2025, 10:00 UTC

Earnings

Danaher 2Q EPS 77c >DHR

22 Jul 2025, 09:34 UTC

Hot Stocks

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 Jul 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 Apr 2025, 10:02 UTC

Earnings

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 Apr 2025, 10:02 UTC

Earnings

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 Apr 2025, 10:02 UTC

Earnings

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 Apr 2025, 10:01 UTC

Earnings

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 Apr 2025, 10:01 UTC

Earnings

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

9.17% upside

12 Months Forecast

Average 243.45 USD  9.17%

High 260 USD

Low 220 USD

Based on 14 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

189.8851 / 196.5Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

111 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat